

CURRICULUM VITAE



NAME Patrick M. Lynch, J.D., M.D.

**PRESENT TITLE
AND AFFILIATION** Associate Professor of Medicine/ Associate Internist
Department of Gastrointestinal Medicine and Nutrition
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

CITIZENSHIP U.S.

HOME ADDRESS 2108 Glen Haven
Houston, Texas 77030
Phone: (713) 664-1913

OFFICE ADDRESS The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Boulevard – Unit 436 (Room FC10.2040)
Houston, Texas 77030
Phone: (713) 794-5073
FAX: (713) 563-4398
E-mail: plynch@mdanderson.org

EDUCATION

Degree-Granting Education

Creighton University School of Law, Omaha, NE, J.D., 1975, Law

Creighton University School of Medicine, Omaha, NE, M.D., 1983, Medicine

Postgraduate Training

Internship, University of Arkansas for Medical Sciences, Little Rock, AR, 1983-1984

Medicine Residency, University of Arkansas for Medical Sciences, Little Rock, AR,
1984-1986

Gastroenterology Fellowship, Baylor College of Medicine, Houston, TX, 1986-1988

CREDENTIALS

Board Certification

Diplomat, American Board of Internal Medicine, 1986

Gastroenterology, Board Eligible, 1988

Licensure

Active: Texas, H3697

Inactive: N/A

EXPERIENCE/SERVICE

Academic Appointments

Law Clerk to General Council, Nebraska Department of Environmental Control, Lincoln, NE, 1974-1975

Research Associate, Department of Preventive Medicine/Public Health, Creighton School of Medicine, Omaha, NE, 1975-1976

Instructor, Department of Preventive Medicine/Public Health, Creighton School of Medicine, Omaha, NE, 1976-1979

Assistant Professor of Medicine/Associate Internist, Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1989-1996

Associate Professor of Medicine/Associate Internist, Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1996-Aug 2000

Associate Professor of Medicine/Associate Internist, Department of Gastrointestinal Medicine and Nutrition, The University of Texas M. D. Anderson Cancer Center, Houston, TX, Sept 2000 –

Academic Administrative Appointments/Responsibilities

Endoscopy Chief, Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1995

Section Chief of Gastroenterology, Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1998-1999

Institutional Committee Activities

Member, Program Committee: "Advances in Biology and Therapy of Colorectal Cancer", 1993
Member, Criteria for Advancement Committee (ad hoc), 1995
Member, Executive Committee of Prevention Faculty, 1997 – 1999
Member, Molecular Diagnostic Laboratory Advisory Committee, 1997 – 2000
Member, Faculty Senate, 2000 – 2003
Member, Quality Assurance Committee (Gastroenterology), 1993 – 1999
Member, Human Cancer Genetics Research Steering Committee, 1997-

Member, Graduate Student Committee, 1997-
Member, CME Advisory Committee, 2000-
Member, Credentials Committee of the Medical Staff, 2001-
Member, Division of Internal Medicine Research Committee, 2004 -
Member, Practitioner Health Committee (LIP), 2005 -

Other Appointments/Responsibilities

Member, NCCN Colorectal Cancer Screening Panel, National Comprehensive Cancer Network, 2003 –

Consultantships – N/A

Military or Other Governmental Service – N/A

HONORS AND AWARDS

Alpha Omega Alpha; Honorary Medical Society, 1983

Listed among "Best Doctors in Houston," *Inside Houston Magazine*, 8/2002, 8/2004

RESEARCH

Grants and Contracts

Medical Advisor, "Hereditary Colon Cancer Newsletter," Kadoorie Fund for Human Cancer Genetics/University Cancer Foundation, 1998-1999, \$ 26,328

Co-Investigator, "Calcium and Aspirin Prevention Trial," National Cancer Institute 2R01 CA 64132-02, 1995-2000, \$ 225,176

Co-Principal Investigator, "Phase I Multiple-Dose Safety and Efficacy Clinical Study of Nonsteroidal Anti-Inflammatory Based Regimens in Adenomatous Polyposis Coli Patients," National Cancer Institute RFP N01-CN-65019-70, 1996-2001, \$ 1,682,630

Collaborator, "Genetic Epidemiology Studies of Peutz-Jeghers Syndrome," American Cancer Society RPG-99-03, Amos (PI), 1999-2001, \$ 101,095

Principal Investigator, "Phase II Multiple-Dose Safety & Efficacy Study of a Selective Inhibitor of Cyclooxygenase-2 or NSAID in HNPCC Patients," National Cancer Institute RFP N01-CN-75021, Lynch (PI), 1997-2003, \$ 1,997,753

Co-Investigator, “Psychosocial Aspects of Genetic Testing for HNPCC,” National Institutes of Health 2R01 HG01200-6, Gritz (PI), 1994-2003, \$1,330,799

Principal Investigator, “Phase I/II Multiple-Dose Safety and Efficacy Study of SC-58635 (Celecoxib) in HNPCC Patients and Carriers,” Searle CS99-325, Lynch (PI), 1999-2003, \$ 84,380

Mentor, “Understanding Family Members Preferences for Contact and Recruitment to Cancer Genetic Studies,” National Society of Genetic Counselors, Michelson (PI), 2003, \$ 1,800

Co-Investigator, “A Phase II Chemoprevention Study of Colorectal ACF Screening, Regression and Prevention in High Risk Patients,” National Cancer Institute N01-CN-05125-02, Bresalier (PI), 2000-2004, \$ 1,942,760 (\$ 300,000/year)

Principal Investigator, “An Observational Registry Assessing Clinical Outcomes in Patients with Familial Adenomatous Polyposis Receiving Celecoxib,” Pharmacia & Upjohn SR2003-00008513DH-01, Lynch (PI), 2003-2005, \$ 200,000

Co-Investigator, “Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Tumors,” M. D. Anderson Institutional Research Grant, Shureiqi (PI), 2003 – 2005, \$ 49,990

Co-Investigator, “Molecular Genetics of Hereditary Nonpolyposis Colorectal Cancer,” National Cancer Institute 5R01 CA070759-08, Frazier (PI), 1997-2006, \$ 419,439

Co-Investigator, “Texas Cancer Genetics Consortium,” National Cancer Institute 5U24 CA078142-05, Strong (PI), 1998-2006, \$ 3,745,371

Principal Investigator, “A Two Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients,” National Cancer Institute N01-CN-95040-04, Lynch (PI), 1999-2006, \$1,631,540

Consultant, “Modulation of Putative Surrogate Endpoint Biomarkers in Endometrial Biopsies from Women with HNPCC,” National Cancer Institute N01-CN-05127-05, Lu (PI), 2000-2006, \$ 2,157,274

Principal Investigator, “A Phase I/II Study of Celecoxib in Genotype-Positive, Phenotype Negative Children with FAP,” National Cancer Institute N01-CN-05126-02, Lynch (PI), 2000-2006, \$ 2,961,771

Co-Investigator, “Expressive Disclosure Program for Colorectal Cancer Patients,” National Cancer Institute R21 CA107306-01, Carmack-Taylor (PI), 2005-2007, \$129,000

Co-Investigator, “15-LOX-1 and Clinical Chemoprevention of Colorectal Tumors,” National Cancer Institute R01-CA106577-01, Shureiqi (PI), 2005-2009, \$197,500

Funded Protocols - N/A**Patents Granted and Pending - N/A****Grant Reviewer/Service on NIH/Other Study Sections**

Member, NCI Scientific Review Group – Subcommittee E Cancer Epidemiology, Prevention and Control, 2001-

Reviewer, European Commission on Cancer Research, 2004 – 2005

Chairman, NCI Scientific Review Group – Subcommittee E Cancer Epidemiology, Prevention and Control, 2005 – 2006

PUBLICATIONS**a. Articles in Peer-Reviewed Journals**

1. Lynch HT, Fritchot BC, **Lynch P**, Lynch J, Guirgis HA. Family studies of malignant melanoma and associated cancer. *Surg Gynecol Obstet* 141:517-22, 1975.
2. Lynch HT, Lynch J, **Lynch P**. Breast cancer genetics and cancer control. *Tumor Association. Arch Surg* 110:1227-29, 1975.
3. **Lynch PM**, Lynch HT. Medical-legal aspects of familial cancer. *J Leg Med* 4:10-16, 1976.
4. **Lynch PM**. Genetics and malpractice; is there a link? Review of article published in *J Leg Med (Medical-legal aspects of familial cancer). Modn Med* 1:106-7, 1976.
5. Lynch HT, Guirgis H, Brodkey F, Maloney K, **Lynch PM**, Rankin L, Lynch J. Early age of onset in familial breast cancer: genetic and cancer control implications. *Arch Surg* 111:126-31, 1976.
6. Lynch HT, Brodkey FD, **Lynch P**, Lynch J, Maloney K, Rankin L, Kraft C, Swartz M, Westercamp T, Guirgis HA. Familial risk and cancer control. *JAMA* 236:582-84, 1976.
7. Lynch HT, Brodkey FD, Guirgis HA, Swartz MJ, Lynch JF, **Lynch PM**. Survival data from a multiphasic mobile cancer detection unit. *Oncology* 33:179-82, 1976.
8. Lynch HT, Mulcahy GM, **Lynch P**, Guirgis H, Brodkey F, Lynch J, Maloney K, Rankin L. Genetic factors in breast cancer: a survey. *Pathol Annu* 11:77-101, 1976.
9. Lynch HT, Harris RE, Guirgis HA, **Lynch PM**, Maloney K, Rankin L, Lynch J. Early age of onset and familial breast cancer. *Lancet* 2:626-7, 1976.
10. **Lynch PM**, Lynch HT, Harris RE. Hereditary proximal colonic cancer. *Dis Colon Rectum* 20:661-68, 1977.

11. Lynch HT, Harris RE, Organ CH, Guirgis HA, **Lynch PM**, Lynch JF. Familial cancer: implications for surgical management of high risk patients. *Surgery* 83:104-13, 1977.
12. Lynch HT, Guirgis HA, **Lynch PM**, Lynch JF, Harris RE. Familial cancer syndromes: a survey. *Cancer* 39:1867-81, 1977.
13. Lynch HT, Harris RE, Organ CH, Guirgis HA, **Lynch PM**, Lynch JF, Nelson EF. The surgeon, genetics, and cancer control: The Cancer Family syndrome. *Ann Surg* 16:435-40, 1977.
14. Lynch HT, Harris RE, Bardawil WA, **Lynch PM**, Guirgis HA, Swartz MJ, Lynch JF. Management of hereditary site-specific colon cancer. *Arch Surg* 112:170-74, 1977.
15. Lynch HT, Harris RE, **Lynch PM**, Guirgis HA, Lynch JF. Role of heredity in multiple primary cancer. *Cancer* 40:1849-54, 1977.
16. Lynch HT, **Lynch PM**, Harris RE. Proximal colon cancer in familial carcinoma of the colon exclusive of familial polyposis coli. *Lancet* 1:1306-7, 1977.
17. Lynch HT, Terasaki PI, Guirgis HA, Sherard BD, Androsch KL, Harris RE, King MC, Petrakis N, Lynch J, Maloney K, Rankin L, **Lynch PM**, Elston R, Mulcahy G, Platt R. HLA in breast cancer-prone families and the cancer family syndrome. *Prog Clin Bio Res* 16:149-62, 1977.
18. Lynch HT, **Lynch PM**, Harris RE. Minimal genetic findings and their cancer control implications: a family with the cancer family syndrome. *JAMA* 240:535-38, 1978.
19. Lynch HT, **Lynch PM**. Genetics and cancer in children. *Pediatr Ann* 7:71-83, 1978.
20. **Lynch PM**, Lynch HT. Genetic counseling of high cancer risk patients: jurisprudential considerations. *Semin Oncol* 5(1):107-18, 1978.
21. Lynch HT, Bardawil WA, Harris RE, **Lynch PM**, Guirgis HA, Lynch JF. Multiple primary cancers and prolonged survival: familial colonic and endometrial cancers. *Dis Colon Rectum* 21:165-68, 1978.
22. Lynch HT, Guirgis HA, Harris RE, Frichot BC, Lynch JF, Vandevoorde JP, **Lynch PM**. Familial clustering of plasma carcinoembryonic antigen (CEA) in the Cancer Family syndrome. *Scand J Immunol* 8:465-70, 1978.
23. Lynch HT, Organ CH Jr, Harris RE, Guirgis HA, **Lynch PM**, Lynch JF. Familial cancer: implications for surgical management of high-risk patients. *Surgery* 83(1):104-13, 1978.
24. Lynch HT, Guirgis HA, Harris RE, **Lynch PM**, Lynch JF, Elston RC, Go RC, Kaplan E. Clinical, genetic, and biostatistical progress in the Cancer Family Syndrome. *Front Gastroint Res* 4:142-50, 1979.
25. Lynch HT, **Lynch PM**, Follett KL, Harris RE. Familial polyposis coli: heterogeneous polyp expression in two kindreds. *J Med Genet* 16:1-7, 1979.

26. Lynch HT, **Lynch PM**. The Cancer Family Syndrome: a pragmatic basis for syndrome identification. *Dis Colon Rectum* 22:106-10, 1979.
27. Lynch HT, Follett KL, **Lynch PM**, Albano WA, Mailliard JL, Pierson RL. Family history in an oncology clinic: Implications for cancer genetics. *JAMA* 242(12):1268-72, 1979.
28. Lynch HT, **Lynch PM**. Tumor variation in the cancer family syndrome: ovarian cancer. *Am J Surg* 138(3):439-42, 1979.
29. Lynch HT, **Lynch PM**, Albano WA, Edney J, Organ CH, Lynch JF. Hereditary cancer: ascertainment and management. *Cancer* 29:216-32, 1979.
30. Fusaro RM, Lynch HT, Pester J, **Lynch PM**. Torre's syndrome as phenotypic expression of cancer family syndrome. *Arc Derm* 116(9):986-7, 1980.
31. Lynch HT, **Lynch PM**, Pester J, Fusaro RM. The cancer family syndrome: rare cutaneous phenotypic linkage of Torre's syndrome. *Arch Intern Med* 141(5):607-11, 1981.
32. Lynch HT, **Lynch PM**, Albano WA, Lynch JF. The Cancer Family syndrome: a status report. *Dis Colon Rectum* 24(4):311-22, 1981.
33. Lynch HT, Albano, WA, Recerbaren J, **Lynch PM**, Lynch JF, Elston R. Prolonged survival as a component of a hereditary breast and nonpolyposis colon cancer. *Med Hypotheses* 7(9):1201-09, 1981.
34. Lynch HT, Lynch JF, **Lynch PM**. Practical aspects of colon cancer genetics. *Prac Gastroent* 5:15-21, 1981.
35. Lynch HT, Albano WA, Recabaren JA, Fain PR, **Lynch PM**. Survival in hereditary breast and colon cancer. (letter) *JAMA* 243(11):1197, 1981.
36. Lynch HT, Albano WA, Lynch JF, **Lynch PM**, Campbell A. Surveillance and managements of patients at high genetic risk for ovarian carcinoma. *Obstet Gynecol* 59(5):589-96, 1982.
37. Lynch HT, Ruma TA, Albano WA, Lynch JF, **Lynch PM**. Phenotypic variation in hereditary adenomatosis: unusual tumor spectrum. *Dis Colon Rectum* 25(3):235-38, 1982.
38. Lynch HT, **Lynch PM**, Albano WA, Lynch JF. Hereditary colon cancer: identifying the high risk person. *Consultant* 22:331-43, 1982.
39. Lynch HT, **Lynch PM**, Lynch JF, Danes BS. What is hereditary colon cancer? *Prog Clin Biol Res* 115:3-38, 1983.
40. **Lynch PM**. Protection of confidentiality and privacy in family studies. *Prog Clin Biol Res* 115:181-98; 1983.
41. Lynch HT, **Lynch PM**, Kimberling WJ, Lynch JF. Medical genetics, Huntington's chorea,

- and legal questions pertaining to autopsy. *Am J Med* 75(1):157-60, 1983.
42. **Lynch PM**, Levin B. Current guidelines for screening high-risk groups for colorectal cancer. *The Cancer Bulletin* 40:200-04, 1988.
 43. **Lynch P**, Winn RJ. Clinical management of hereditary non-polyposis colon cancer. High-risk clinics and registries. *Hematol Oncol Clin North Am* 3(1):75-86, 1989.
 44. Lynch HT, Smyrk T, **Lynch PM**, Lanspa SJ, Boman BM, Ens J, Lynch JF, Strayhorn P, Carmody T, Cristofaro G. Adenocarcinoma of the small bowel in Lynch syndrome II. *Cancer* 64:2178-83, 1989.
 45. **Lynch P**, Green L, Jordan PH, Graham DY. Hepatocellular carcinoma metastatic to the stomach presenting as bleeding craterogenic ulcers. *Am J Gastroenterol* 84(6):653-55, 1989.
 46. Lynch HT, Lanspa SJ, Boman BM, Smyrk T, Watson P, Lynch JF, **Lynch PM**, Cristofaro G, Bufo P, Tauro AV, et al. Hereditary non-polyposis colorectal cancer. Lynch syndromes I and II. *Gastroenterol Clin North Am* 17(4):679-712, 1989.
 47. Lynch HT, Smyrk TC, Lanspa SJ, **Lynch PM**, Watson P, Strayhorn PC, Bronson EK, Lynch JF, Priluck IA, Appelman HD. Phenotype variation on colorectal adenoma cancer expression on two families: hereditary flat adenoma syndrome. *Cancer* 66(5):909-15, 1990.
 48. Rouben LD, David C, Dubrow R, Faintuch J, **Lynch P**, Fornage B, Levin B. Endoscopic ultrasonography on staging rectal cancer. *Am J Gastro* 85(10):1391-94, 1990.
 49. Lynch HT, Smyrk T, Watson P, Lanspa SJ, Boman BM, **Lynch PM**, Lynch JF, Cavalieri J. Hereditary colorectal cancer. *Semin Oncol* 18(4):337-66, 1991.
 50. Wargovich MJ, **Lynch PM**, Levin B. Modulating effects of calcium in animal models of colon carcinogenesis and short-term studies in subjects at increased risk for colon cancer. *Am J Clin Nutr* 54(1):202S-05S, 1991.
 51. **Lynch PM**, Wargovich MJ, Lynch HT, Palmer C, Lanspa S, Drouhard T, Lynch J. A follow-up study of colonic epithelial proliferation as a biomarker in a native American family with hereditary nonpolyposis colon cancer. *J Natl Cancer Inst* 83(13):951-54, 1991.
 52. Daneker GW Jr, Carlson GW, Hohn DC, **Lynch P**, Rouben L, Levin B. Endoscopic laser recanalization is effective for prevention and treatment of obstruction in sigmoid and rectal cancer. *Arch Sur* 126(11):1348-52, 1991.
 53. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, **Lynch PM**, Jenkins JX, Rouse J, Cavaliere J, Howard L, Lynch J. Hereditary flat adenoma syndrome: a variant of familial adenomatous polyposis? *Dis Colon Rectum* 35(5):411-21, 1992.
 54. Spirio L, Otterud B, Stauffer D, Lynch H, **Lynch P**, Watson P, Lanspa S, Smyrk JT, Cavaliere J, Howard L, Burt R, White R, Leppert M. Linkage of a variant or attenuated form of adenomatous polyposis coli to the adenomatous polyposis coli (APC) locus. *Am J Hum*

- Genet 51:92-100, 1992.
55. Wargovich MJ, Isbell G, Shabot M, Winn R, Lanza F, Hochman L, Larson E, **Lynch P**, Roubein L, Levin B. Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma. *Gastroenterol* 103:92-97, 1992.
 56. Morris L, **Lynch PM**, Gleason WA, Schauder C, Pinkel D, Duvic M. Blue Rubber Bleb Nevus Syndrome: Laser photocoagulation of colonic hemangiomas in a child with microcytic anemia. *Pediatr Dermatol* 9(2):91-4, 1992.
 57. Catalano M, **Lynch PM**, Cleary K, Levin B, Raijman I, Schwarz P, Roubein L. Turcot's Syndrome. *Cancer Bulletin* 44:151-53, 1992.
 58. Vasen HF, Mecklin JP, Watson P, Utsunomiya J, Bertario L, **Lynch P**, Svendsen LB, Cristofaro G, Muller H, Khan PM, Lynch HT. Surveillance in hereditary nonpolyposis colorectal cancer: an international cooperative study of 165 Families. *Dis Colon Rectum* 36(1):1-4, 1993.
 59. Lynch, HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, **Lynch PM**, Cavalieri RJ, Boland CR. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. *Gastroenterol* 104:1535-49, 1993.
 60. Lynch HT, Smyrk T, Lanspa S, Jenkins JX, **Lynch PM**, Cavalieri J, Lynch JF. Upper gastrointestinal manifestations in families with hereditary flat adenoma syndrome. *Cancer* 71(9):2709-14, 1993.
 61. Roubein LD, DuBrow R, David C, **Lynch P**, Fornage B, Ajani J, Roth J, Levin B. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophogogastric junction. *Endoscopy* 25:587-91, 1993.
 62. Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G, Gelbert L, Thliveris A, Carlson M, Otterud B, Lynch H, Watson P, **Lynch PM**, Laurent-Puig P, Burt R, Thomas G, Leppert M, White R. Alleles of the APC gene: An attenuated form of familial polyposis. *Cell* 75(5):951-57, 1993.
 63. Ender B, **Lynch P**, Kim YH, Inamdar NV, Cleary KR, Frazier ML. Overexpression of an elongation factor 1 gamma-hybridizing RNA in colorectal adenomas. *Mol Carcinog* 7(1):18-20, 1993.
 64. **Lynch PM**: Surveillance in Hereditary nonpolyposis colorectal cancer. *Surg Oncol Clin N Am* 3(3):479-99, 1994.
 65. **Lynch PM**, Howard LD, Pleasants LM, Hansen MF. Clinical aspects and genetics of APC and HNPCC patients. *Cancer Bulletin* 46(4):315-20, 1994.
 66. **Lynch PM**, Skibber J. Perspectives in prevention: screening guidelines. *Cancer Bulletin* 46(4):359-64, 1994.

67. Lynch HT, Drouhard T, Lanspa S, Smyrk T, **Lynch P**, Lynch J, Vogelstein B, Nystrom-Lahti M, Sistonen P, Peltomaki P, de la Chappelle A. Mutation of an mutL homologue in a Navajo family with hereditary nonpolyposis colon cancer. *J Natl Cancer Inst* 86:(18) 1417-19, 1994.
68. Lahti MN, Parsons R, Sistonen P, Pytkkanen L, Aaltonen LA, Leach FS, Hamilton SR, Watson P, Bronson E, Fusaro R, Cavalieri J, Lynch J, Lanspa S, Smyrk T, **Lynch PM**, Drouhard T, Kinzler KW, Vogelstein B, Lynch HT, de la Chappelle A, Peltomaki P. Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. *Am J Hum Genet* 55:659-65, 1994.
69. **Lynch PM**. Surveillance and treatment of hereditary nonpolyposis colorectal cancer. *Anticancer Res* 14:1641-46, 1994.
70. Ajani JA, Ilson DH, Daugherty K, Pazdur R, **Lynch PM**, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 86:1086-91, 1994.
71. **Lynch PM**. Hereditary nonpolyposis colorectal carcinoma (HNPCC): clinical application of molecular diagnostic testing. (Review). *Ann Med* 26(3):221-8, 1994.
72. Rich, TA, Skibber, JM, Ajani, JA, Buchholz, DJ, Cleary, KR, Dubrow, RA, Levin, B, **Lynch, PM**, Meterissian, SH, Roubein, LD, Ota, DM: Preoperative infusional chemoradiation for stage T3 rectal cancer. *Int J Rad Oncol Biol Phys* 32:1025-9, 1995.
73. Terry NH, Meistrich ML, Roubein LD, **Lynch PM**, Dubrow RA, Rich TA. Cellular kinetics in rectal cancer. *Brit J Cancer* 72:435-41, 1995.
74. **Lynch, PM**: Biology of gastric cancer: Gastritis-metaplasia-dysplasia sequence, role of H Pylori, and molecular correlates of tumor progression. *J Infus Chemother* 5:93-6, 1995
75. Kim YH, Ajani JA, Ota DM, **Lynch PM**, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. *Cancer* 75:451-6, 1995
76. Ajani JA, Roth JA, Putnam, JB, Walsh G, **Lynch PM**, Roubein LD, Ryan MB, Natrajan G, Gould P. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. *Eur J Cancer* 31A(5):665-70, 1995.
77. ASCO Subcommittee on Genetic Testing for Cancer Susceptibility: Statement of the American Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility. *JCO* (May), 1996.
78. Jeon HM, **Lynch PM**, Howard L, Ajani J, Levin B, Frazier ML: Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. *Hum Mutat* 7:327-333, 1996.

79. Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM, Zou TT, Shi YQ, Lei J, Cottrell J, Cymes K, Biden K, Simms L, Leggett B, **Lynch PM**, Frazier M, Powell SM, Harpaz N, Sugimura H, Young J, and Meltzer SJ: Microsatellite instability in the insulin-like growth factor II receptor in gastrointestinal tumours. *Nat Genet* 14(3):255-257, 1996.
80. Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, **Lynch PM**, Charnsangavej C: Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. *J Clin Onc* 14(8):2311-2315, 1996.
81. Roubain, LD, **Lynch, PM**, Globber, G, Sinicrope, FA: Interobserver variability in endoscopic ultrasonography: a prospective evaluation. *Gastrointest Endosc* 5:573-577, 1996.
82. Burke W, Petersen G, **Lynch P**, Botkin J, Daly M, Garber J, Kahn MJ, McTiernan A, Offit K, Thomson E, Varricchio C: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. *JAMA* 277 (11): 915-919, 1997.
83. Burke W, Daly M, Garber J, Botkin J, Kahn MJE, **Lynch P**, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C: Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2. *JAMA* 277(12):997-1003, 1997.
84. Vernon SW, Gritz ER, Peterson SK, Amos CI, Perz CA, Baile WF, **Lynch PM**: Correlates of psychologic distress in colorectal cancer patients undergoing genetic testing for hereditary colon cancer. *Health Psychol* 16(1):73-86, 1997.
85. Yin J, Kong D, Wang S, Zou TT, Souza RE, Smolinski K, **Lynch PM**, Hamilton SR, Sugimura H, Powell SM, Young J, Abraham JM, Meltzer SJ: Mutation of hMSH3 and hMSH6 Mismatch Repair Genes in Genetically Unstable Human Colorectal and Gastric Carcinomas. *Hum Mutat* 10:474-478, 1997.
86. Raijman I, **Lynch P**, Sinicrope F, Leveritt S, Globber G: Coated expandable esophageal stents in the treatment of digestive-respiratory fistulae (DRF). *Am J Gastro* 92:2188-91, 1997.
87. Raijman I, Siddique I, **Lynch P**: Does chemoradiation therapy increase the incidence of complications with self-expanding coated stents in the management of malignant esophageal strictures. *Am J Gastro* 92:2192-6, 1997.
88. **Lynch P**, Severin M, Mills A, Bosserman L, Carson D, Chambers DC, Cunningham M, Sung M, Vogelzang NJ: Medical/legal issues in genetic testing: workshop no. 3. *Cancer* 80(3):630-631, 1997.
89. Vernon SW, Gritz ER, Peterson SK, Amos CI, Baile WF, Perz CA, **Lynch PM**. Design and methodology of a study of psychosocial aspects of genetic testing for hereditary colon cancer. *Ann NY Acad Sci* 833:190-194, 1997.
90. Konishi H, Steinbach G, Terry NH, Fujita K, Lee JJ, Ruifrok A, Spaulding D, **Lynch PM**, Dubin JA, Andreeff M, Goodacre AM, Hattori T, Hittelman WN: S phase determination in

- intact colonic crypts by histone H3 messenger RNA in situ hybridation and confocal microscopy. *Cancer Epidemiol Biomarkers Prev* 6:531-536, 1997.
91. Amos CI, Bali D, Thiel TJ, Anderson JP, Gourley I, Frazier ML, **Lynch PM**, Luchtefeld MA, Young A, McGarrity TJ, Seldin MF: Fine mapping of a genetic locus for Peutz-Jeghers syndrome on chromosome 19p. *Ca Res* 57(17):3653-6, 1997.
 92. Raijman I, Siddique I, Ajani J, **Lynch P**: Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. *Gastro Endo* 48(2):172-179, 1998.
 93. Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R, Ajani J, Rich TA, Goswitz MS, Evetts PA, Allen PK, **Lynch PM**, Skibber JM: Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. *Radiother Oncol* 51(2):153-60, 1999.
 94. Lynch HT, Paulson J, Severin M, Lynch J, **Lynch P**: Failure to diagnose hereditary colorectal cancer and its medicolegal implications. *Dis Colon Rectum* 42(1):31-35, 1999.
 95. Lynch HT, **Lynch PM**. Negative genetic test result in familial adenomatous polyposis: clinical screening implications. *Dis Colon Rectum* 42(3):310-312, 1999.
 96. Gritz ER, Vernon SW, Peterson SK, Baile WB, Marani SK, Amos CI, Frazier ML, **Lynch PM**: Distress in the cancer patient and its association with genetic testing and counseling for hereditary nonpolyposis colon cancer. *Cancer Res Ther Control* 8:35-49, 1999.
 97. Lin X, Choi JH, **Lynch P**, Xi L, Wu E, Frazier ML. Reduction in *hMSH2* mRNA levels by premature translation termination: implications for mutation screening in hereditary nonpolyposis colorectal cancer. *Dig Dis Sci* 44(3):553-559, 1999.
 98. Roth S, Sistonen P, Salovaara R, Hemminki A, Loukola A, Johansson M, Avizienyte E, Cleary KA, **Lynch P**, Amos CI, Kristo P, Mecklin JP, Kellokumpu I, Jarvinen H, Aaltonen LA. SMAD genes in juvenile polyposis. *Genes Chromosomes Cancer* 26(1):54-61, 1999.
 99. Frazier ML, Sinicrope FA, Amos CI, Cleary KR, **Lynch PM**, Levin B, Luthra R. Loci for efficient detection of microsatellite instability in hereditary non-polyposis colorectal cancer. *Oncology Reports* 6(3):497-505, 1999.
 100. Sinicrope FA, Lemoine M, Xi L, **Lynch PM**, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. *Gastroenterology* 117(2):350-358, 1999.
 101. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, **Lynch PM**, Guber G, Wolff R, Rich TA, Skibber J. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M.D. Anderson Cancer Center experience. *Int J Radiat Oncol Biol Phys* 44(5):1027-1038, 1999.
 102. Steinbach G, Ford R, Guber G, Sample D, Hagemester FB, **Lynch PM**, McLaughlin PW,

- Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. *Ann Intern Med* 131(2):88-95, 1999.
103. **Lynch PM.** Clinical challenges in management of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. *Cancer* 86(8):1713-1719, 1999.
104. Ajani JA, Mansfield PF, **Lynch PM**, Pisters PW, Feig B, Dumas P, Evans EB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. *JCO* 17(8):2403-11, 1999.
105. Su LK, Steinbach G, Sawyer JC, Hindi M, Ward PA, **Lynch PM.** Genomic rearrangements of the *APC* tumor-suppressor gene in familial adenomatous polyposis. *Hum Genet* 106:101-107, 2000.
106. Ibrahim NK, Sahin AA, Dubrow RA, **Lynch PM**, Michaud LB, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. *Lancet* 355:281-283, 2000.
107. Steinbach G, **Lynch PM**, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 342(26):1946-1952, 2000.
108. Janjan NA, Crane CH, Feig BW, Cleary K, Dubrow R, Curley S, Ellis LM, Vauthey J-N, Lenzi R, **Lynch P**, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Skibber J. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys* 47(3):713-718, 2000.
109. Kong S, Amos CI, Luthra R, **Lynch PM**, Levin B, Frazier ML: Effects of cyclin D1 polymorphism on age of onset of hereditary non-polyposis colorectal cancer. *Cancer Res* 60(2):249-252, 2000.
110. Su LK, Barnes CJ, Yao W, Qi Y, **Lynch PM**, Steinbach G. Inactivation of germline mutant *APC* alleles by attenuated somatic mutations: a molecular genetic mechanism for attenuated familial adenomatous polyposis. *Am J Hum Genet* 67(3):582-90, 2000.
111. Frazier ML, Su LK, Amos CI, **Lynch PM.** Current applications of genetic technology in predisposition testing and microsatellite instability assays. *J Clin Oncol* 18(21Suppl):70S-4S, 2000.
112. Komaki R, Janjan NA, Ajani JA, **Lynch PM**, Fairweather JS, Raijman I, Blumenshein GR, Ho L, Pisters PWT, Feig BW, Walsh GL, Pazdur R. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. *Oncology (Huntingt)* 14(12 Suppl 14):34-37, 2000.

113. Crane CH, Janjan NA, Abbruzzese JL, Curley S, Vauthey J-N, Sawaf HB, Dubrow R, Allen P, Ellis LM, Hoff P, Wolff RA, Lenzi R, Brown TD, **Lynch P**, Cleary K, Rich TA, Skibber J. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. *Int J Rad Onc Biol Phys* 49(1):107-116, 2001.
114. Frazier ML, O'Donnel FT, Kong S, Xianjun G, Campos I, Luthra R, **Lynch PM**, Amos CI. Age associated risk of cancer among individuals with *N*-Acetyltransferase 2 (*NAT2*) mutations and mutations in DNA mismatch repair genes. *Cancer Res* 61:1269-1271, 2001.
115. **Lynch PM**: COX-2 inhibition in clinical cancer prevention. *Oncology (Huntingt)* 15(3 Suppl 5):21-26, 2001.
116. Kong S, Wei Q, Amos CI, **Lynch PM**, Levin B, Zong J, Frazier ML. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. *J Natl Cancer Inst* 93(14):1106-1108, 2001.
117. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, **Lynch PM**, Vaporciyan A, Smythe R, Lahoti S, Rajman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. *Cancer* 92(2):279-86, 2001.
118. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, **Lynch P**, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. *Amer J Clin Onc* 24(2):107-112, 2001.
119. Wu G, Wu W, Hegde M, Fawkner M, Chong B, Love D, Su LK, **Lynch P**, Snow K, Richards CS. Detection of sequence variations in the adenomatous polyposis coli (*APC*) gene using denaturing high-performance liquid chromatography. *Genet Test* 5(4):281-290, 2001.
120. Phillips RK, Wallace MH, **Lynch PM**, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G, FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. *Gut* 50(6):857-860, 2002.
121. Su LK, Kohlmann W, Ward PA, **Lynch PM**. Different familial adenomatous polyposis phenotypes resulting from deletions of the entire *APC* exon 15. *Hum Genet* 111:88-95, 2002.
122. Howe JR, Shellnut J, Wagner B, Ringold JC, Sayed MG, Ahmed AF, **Lynch PM**, Amos CI, Sistonen P, Aaltonen LA. Common deletion of *SMAD4* in juvenile polyposis is a mutational hotspot. *Am J Hum Genet* 70(5):1357-1362, 2002.
123. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, **Lynch P**, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. *Gastric Cancer* 5(4):208-212, 2002.

124. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd C-J, DeNobile J, Soballe P, Simon R, Wright G, **Lynch P**, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Distinguishing right from left colon by the pattern of gene expression. *Cancer Epidebm Biomar* 12:755-762, 2003.
125. Frazier ML, Xi L, Zong J, Viscofsky N, Rashid A, Wu EF, **Lynch PM**, Amos CI, Issa JP. Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. *Cancer Res* 15;63(16):4805-4808, 2003.
126. Lynch HT, Cristofaro G, Rozen P, Vasen H, **Lynch P**, Mecklin JP, St John J. History of the International Collaborative Group on Hereditary Non Polyposis Colorectal Cancer. *Familial Cancer* 2(suppl 1):3-5, 2003.
127. Sinicrope FA, Half E, Morris JS, **Lynch PM**, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC, Familial Adenomatous Polyposis Study Group. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. *Cancer Epidemiol Biomarkers Prev* 13(6):920-927, 2004.
128. Cotton PB, Durkalski VL, Pineau BC, Palesch YY, Mauldin PD, Hoffman B, Vining D, Small WC, Affronti J, Rex D, Kopecky KK, Ackerman S, Burdick JS, Brewington C, Turner MA, Zfass A, Wright AR, Iyer RB, **Lynch P**, Sivak MV, Butler H. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. *JAMA* 291(14):1713-1719, 2004.
129. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, **Lynch PM**, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. *Amer J Gastroenterol* 99(7):1258-1266, 2004.
130. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, **Lynch PM**, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially respectable gastric carcinoma. *J Clin Oncol* 22(14):2774-2780, 2004.
131. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, **Lynch PM**, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. *Dis Esophagus* 17(1):38-43, 2004.
132. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB Jr, **Lynch PM**, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. *Cancer* 100(11):2347-2354, 2004.
133. Broaddus RR, **Lynch PM**, Lu KH, Luthra R, Michelson SJ. Unusual tumors associated with

- the hereditary nonpolyposis colorectal cancer syndrome. *Mod Pathol* 17(8):981-989, 2004.
134. Amos CI, Keitheri-Cheteri MB, Sabripour M, Wei C, McGarrity TJ, Seldin MF, Nations L, **Lynch PM**, Fidler HH, Friedman E, Frazier ML. Genotype-phenotype correlations in Peutz-Jeghers syndrome. *J Med Genet* 41(5):327-333, 2004.
 135. Xiao Z, Luke BT, Izmirlian G, Umar A, **Lynch PM**, Phillips RK, Patterson S, Conrads TP, Veenstra TD, Greenwald P, Hawk ET, Ali IU. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. *Cancer Res* 64(8):2904-2909, 2004.
 136. Jones JS, Gu X, Campos IM, **Lynch PM**, Amos CI, Frazier ML. GSTM1 polymorphism does not affect hereditary nonpolyposis colorectal cancer age of onset. *Cancer Epidemiol Biomarkers Prev* 13(4):676-678, 2004.
 137. Abraham SC, Park SJ, Cruz-Correa M, Houlihan PS, Half EE, **Lynch PM**, Wu TT. Frequent CpG island methylation in sporadic and syndromic gastric fundic gland polyps. *Am J Clin Pathol* 12:740-746, 2004.
 138. Jones JS, Chi, X, Gu X, **Lynch PM**, Amos CI, Frazier ML. P53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. *Clin Ca Res* 10 (17):5845-5849, 2004
 139. Lu K, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen L, Allen B, Conrad P, Terdiman L, Sun C, Burke T, Gershenson D, Lynch H, **Lynch P**, Broaddus R. Gynecologic cancer as a “Sentinel Cancer” for women with hereditary non-polyposis colorectal cancer syndrome. *Obstetrics and Gynecology* 105(3) 569-74, 2005.
 140. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, **Lynch PM**, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. *JCO* 23(6):1237-1244, 2005.
 141. Gritz ER, Peterson SK, Vernon SW, Marani SK, Baile WF, Watts BG, Amos CI, Frazier ML, **Lynch PM**. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. *JCO* 23(9):1902-1910, 2005.
 142. Jones JS, GuX, **Lynch PM**, Rodriguez-Bigas M, Amos CI, Frazier ML. ATM polymorphism and hereditary Nonpolyposis colorectal cancer (HNPCC) age of onset (United States). *Cancer Causes Control* 16(6):749-753, 2005.
 143. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, **Lynch PM**, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative Chemoradiotherapy for carcinoma of the esophagus. *Cancer* 104(7):1349-1355, 2005.
 144. Pentz RD, Peterson SK, Watts B, Vernon SW, **Lynch PM**, Koehly LM, Gritz ER. Hereditary nonpolyposis colorectal cancer family members’ perceptions about the duty to inform and health professionals’ role in disseminating genetic information. *Genet Test* 9(3):261-8, 2005.

145. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris J, Yang P, Newman RA, Broaddus RR, Hamilton SR, **Lynch P**, Levin B, Fischer S, Lippman S. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. *Cancer Res* 65(24):11486-11492, 2005.
146. Zecevic M, Amos CI, Gu X, Campos IM, Jones JS, **Lynch PM**, Rodriguez-Bigas MA, Frazier ML. ICF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. *JNCI* 98(2):139-143, 2006.
147. Lynch HT, Boland CR, Gong G, Shaw TG, **Lynch PM**, Fodde R, Lynch JF, de la Chapelle A. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. *Eur J Hum Genet* 2006 Feb 15; Review
148. Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, **Lynch PM**, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN. Genetic/familial high-risk assessment: breast and ovarian. *J Natl Compr Canc Netw*. 4(2):156-76, 2006.
149. Jones JS, Amos CI, Pande M, Gu X, Chen J, Campos IM, Wei Q, Rodriguez-Bigas M, **Lynch PM**, Frazier ML. DNMT3b polymorphis and hereditary nonpolyposis colorectal cancer age of onset. *Cancer Epidemiol Biomarkers Prev* (Accepted)
150. Ross W, **Lynch P**, Ajani J, Lee JH, Ayers GD. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulae. *Gastrointest Endosc* (Accepted April 2006)
151. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Ho L, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Zhongxing L, **Lynch PM**, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Persistent malignant lymphadenopathy after pre-operative chemoradiation for esophageal carcinoma identifies patients with poor post-operative survival. (submitted)
152. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd C-J, DeNobile J, Soballe P, **Lynch P**, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. *Cancer Epidemiol Biomarkers Prev* (Submitted)
153. Chen J, Sen S, Amos CI, Jones JS, **Lynch P**, Rodriguez-Bigas M, Frazier ML. Association between STK15/aurora-A kinase polymorphism and age of onset of hereditary Nonpolyposis colorectal cancer in a Caucasian population. *Cancer Research* (Submitted)

b. Invited Articles

1. Abu-Hamda EM, Hattab EM, **Lynch PM**. Small bowel tumors. *Curr Gastroenterol Rep* 5(5):386-393, 2003.
2. **Lynch PM**. Cancer screening guidelines and prevention factors for high-risk patients with a family history of colorectal cancer. *Current Colorectal Cancer Reports* 1(2):110-116, 2005.

3. **Lynch PM.** Current approaches in familial colorectal cancer: a clinical perspective. JNCCN (In Press)

c. Editorials

1. **Lynch PM.** If aggressive surveillance in hereditary nonpolyposis colorectal cancer (HNPCC) is now state-of-the-art, are there any challenges left? *Gastroenterology* 118:969-977, 2000.
2. **Lynch PM.** Screening colonoscopy for family history of colorectal cancer: a growing consensus. *Ann Surg Oncol* 9(5):425-427, 2002.
3. Lynch HT, **Lynch PM.** Molecular screening for the Lynch syndrome – better than family history? *NEJM* 352(18):1920-1922, 2005.

d. Other Articles

1. **Lynch PM.** Commentary. Chan AT et al. (2005) Does regular use of aspirin reduce the risk of colorectal cancer? *Nature Clinical Practice Oncology* 3(4): 187, 2006.

e. Abstracts

1. Ajani JA, Mansfield PF, Janjan N, Pisters P, **Lynch P**, Raijman I, Pazdur R, Goswitz M, Feig B, Hargraves K, Myerson R, and Gunderson L. Preoperative chemoradiation therapy (CIRT) in patients with potentially resectable gastric carcinoma: a multi-institutional pilot. ASCO 1998.
2. Nesbitt J, Ajani JA, Komaki R, Walsh G, Putnam J, Swisher S, Pisterse P, **Lynch P**, Raijman I, Pazdur R, Delclos M, Martin F, and Roth J. Preoperative taxol-based chemotherapy followed by chemoradiation therapy in patients with potentially resectable esophageal carcinoma. ASCO 1998.
3. Janjan NA, Skibber J, Feig BW, Cleary K, Dubrow R, Goswitz M, Ellis L, Curley S, **Lynch P**, Wolff R, Abbruzzese J. Preoperative Concomitant Boost Radiotherapy with Continuous Infusion 5-Fluorouracil for Locally Advanced Rectal Cancer: Preliminary Analysis of Surgical and Pathologic Outcomes. Proceedings of the 40th Annual ASTRO Meeting, 1998.
4. **Lynch PM**, Steinbach G, Hittelman W, Terry N, Frazier M, Abbruzzese J, Gordon G, Hawk E, Kirsch I, Lynch H. A phase II chemoprevention trial in HNPCC utilizing a selective cyclooxygenase 2 inhibitor: protocol description and progress to date. *J Gastroenterol Hepatol* 14(8):A59, 1999.
5. Sinicrope FA, Lemoine M, Xi L, **Lynch PM**, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase-2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. *J Gastroenterol Hepatol* 14(8):A59, 1999.
6. Frazier ML, Amos CI, Cleary KR, Gritz E, Watts B, **Lynch P**, Luthra R. Mutations in hereditary nonpolyposis colon cancer (HNPCC) cases. *J Gastroenterol Hepatol* 14(8):A60, 1999.
7. Amos CI, **Lynch PM**, Cleary KR, McGarrity TJ, Seldin MF, Anderson JP, Frazier ML.

- Genetic epidemiology of Peutz-Jeghers syndrome. *J Gastroenterol Hepatol* 14(8):A78, 1999.
8. Janjan NA, Crane CH, Feig BW, Cleary K, Dubrow R, Curley S, Ellis LM, Vauthey N, Lenzi R, **Lynch P**. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. *Intl J Radiat Oncol Biol Phys* 45(3): 177 (A60), 1999.
 9. Brown T, Janjan NA, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey N, **Lynch P**, Ellis LM, Wolff R. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. *Intl J Radiat Oncol Biol Phys* 45(3):339 (A2122), 1999.
 10. Steinbach G, **Lynch PM**, Phillips R, Wallace M, Hawk E, Gordan G, Sherman J, Wakabayashi N, Saunders B, Shen Y, Godio L, Patterson S, Abbruzzese J, Jester S, King K, Zimmerman S, Levin B. Effect of celecoxib on colorectal polyps in patients with familial adenomatous polyposis (FAP). *Am J Gastroenterol* 1999.
 11. Barnes CJ, Steinbach G, Hittelman WN, **Lynch PM**, Terry NHA, Su L-K. Isolation, confocal microscopy, and molecular analysis of intact colon epithelial structures from pancancerous lesions of individuals with an inherited risk for colorectal cancer. American Association for Cancer Research, March 1999.
 12. Amos CI, Newsome M, Cleary KR, McGarrity TJ, Seldin MF, **Lynch PM**, Anderson JP, Frazier ML. Genetic epidemiology of Peutz-Jeghers syndrome. *Am Assoc Cancer Res* 40:465, 1999.
 13. Amos CI, Frazier ML, **Lynch PM**, McGarrity TJ. Genetic studies of Peutz-Jeghers syndrome. *Am J Med Genet* 67:S83, 2000.
 14. Peterson SK, Watts BG, **Lynch PM**, Vernon SW, Kapoor S, Gritz ER. Family characteristics associated with nonreferral of relatives for HNPCC genetic counseling and testing. *Am J Human Genetics* 71(S4):239, 2002.
 15. Half E, Su L-K, Lunagomez S, Steinbach G, Patterson S, Phillips RK, Latchford A, Hawk E, **Lynch PM**. Response to celecoxib in familial adenomatous polyposis (FAP) does not depend on genotype or adenoma burden. *DDW* 2004.
 16. Peterson SK, **Lynch PM**, Burke C, Church J, Hasson H, Hawk E. Psychosocial evaluation of children and parents involved in a phase I study of celecoxib in children with FAP. *CGA* 2004 (submitted).
 17. Peterson SK, Askins MA, Watts BG, Burke CA, Hasson H, Church J, Schover LR, Hawk E, **Lynch PM**. Family resiliency and functioning among families with APC-positive children. *Familial Cancer* 4 (S1):49-50 (A F31), 2005.
 18. **Lynch P**, Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Benfield R, Half E, Miller D, Ayers GD. Colonoscopy in a phase I safety trial of celecoxib in children with FAP. *Familial Cancer* 4 (S1):57 (A F42), 2005.

19. Burke CA, **Lynch P**, Phillips R, Hawk E, Church J, Hasson H, Miller D, Burke S. Considerations for maximizing randomization in chemoprevention trials in FAP. *Familial Cancer* 4 (S1):76-77 (A P27), 2005.
20. Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Benfield R, Half E, Miller D, Ayers GD, **Lynch P**. Design and primary safety outcome in a phase I trial of celecoxib in children with FAP. *Familial Cancer* 4 (S1):77-78 (A P29), 2005.
21. Lu KH, Watts BG, Soliman PT, Boyd-Rogers SG, Daniels MS, Broaddus RR, **Lynch PM**, Peterson SK. A prospective pilot study of combined colon and endometrial cancer screening in women with HNPCC. *Familial Cancer* 4 (S1):104-105 (A P83), 2005
22. Peterson SK, Watts BG, McGivern B, Burke S, Latchford A, Phillips R, Burke C, Church J, Hasson H, **Lynch PM**. FAP-affected adults' responses to reported cardiovascular risks associated with celecoxib. CGA 2005 (submitted)
23. **Lynch P**, Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Ayers D. Efficacy and safety in a phase I safety trial of celecoxib in children with FAP. AGA 2005 (submitted)

f. Book Chapters

1. Lynch HT, **Lynch PM**, Lynch J, et al. Management and control of familial cancer. In: JJ Mulvihill, RW Miller, J Fraumeni (eds). *Genetics of Human Cancer: Progress in Cancer Research and Therapy*. Raven Press, New York; 1977, pp 235-56.
2. Lynch HT, Terasaki PI, Guirgis HA, Sherard BD, Androsch KL, Harris RE, King MC, Petrakis N, Lynch J, Maloney K, Rankin L, **Lynch PM**, Elston R, Mulcahy G, Platt R. HLA in breast cancer prone families and the Cancer Family Syndrome. IN: GP Murphy (ed). *Progress in Clinical and Biological Research*. Liss, New York; 1977, pp 248.
3. **Lynch PM**, Lynch HT, Harris RE, Lynch JF, Guirgis HA: Heritable colon cancer and solitary adenomatous polyps. In: He Nieburgs (ed). *Prevention and Detection of Cancer*, Part I, Vol. 2. Marcel-Dekker, New York; 1978, pp 1573-89.
4. Lynch J, Lynch HT, Guirgis H, Brodkey F, Maloney K, Kraft C, Swartz M, Westercamp T, Rankin L, **Lynch PM**. Mobile screening: epidemiologic and cancer control model. In: NE Nieburgs (ed). *Prevention and Detection of Cancer*, Part I, Vol. 2 Marcel-Dekker, New York; 1978, pp. 1251-61.
5. Lynch HT, **Lynch PM**. Constitutional factors and endometrial carcinoma. In: NE Nieburgs (ed). *Prevention and Detection of Cancer*, Part I, Vol.2. Marcel-Dekker, New York; 1978, pp 2105-17.
6. Lynch HT, **Lynch PM**, Lynch JF. Genetic counseling and cancer. In: S. Kessler (ed). *Genetic Counseling: Psychological Dimensions*. Academic Press, New York; 1979, pp 221-41.
7. Lynch HT, **Lynch PM**, Guirgis HA. Host-environmental interaction and carcinogenesis in

- man. In: R. Kouri (ed). *Genetic Differences in Chemical Carcinogenesis*. CRC Press, Boca Raton, 1980.
8. Lynch HT, **Lynch PM**, Lynch JF. Analysis of genetics of inherited colon cancer. In: SJ Winawer, D Schottenfeld, P Sherlock (eds). *Progress in Cancer Research and Therapy: Prevention, Epidemiology, Screening*. Raven Press, New York; 1980, pp 117-31.
 9. Lynch HT, Albano WA, Danes BS, Lynch J, **Lynch PM**. Precursor conditions and monitoring of high risk colon cancer patients. In: JR Stroehlein, MM Romdahl (eds). *Gastrointestinal Cancer*. Raven Press, New York; 1981, pp 297-25.
 10. Lynch HT, Albano WA, **Lynch PM**, Lynch JF. Hereditary breast cancer: identification, natural history, and managements. In: RG Margoese (ed). *Contemporary Issues in Clinical Oncology*. Churchill-Livingstone, New York; 1983, pp 157-60.
 11. **Lynch PM**. Protection of confidentiality and privacy in family studies. In: JRF Ingall (ed). *Genetics of Colorectal Cancer*. Liss, New York, 1983.
 12. Lynch HT, **Lynch PM**, Keathley J. Epidemiology of colon cancer. In: PM Lynch, HT Lynch (eds), *Colon Cancer Genetics*. Van Nostrand Reinhold Co., New York, 1985.
 13. **Lynch PM**. Hereditary nonpolyposis colon cancer: epidemiological and clinic-genetic features. In: PM Lynch, HT Lynch (eds). *Colon Cancer Genetics*. Van Nostrand Reinhold Co., New York, 1985.
 14. Lynch HT, **Lynch PM**. Biological and clinical nuances in hereditary colon cancer. In: PM Lynch, HT Lynch (eds). *Colon Cancer Genetics*. Van Nostrand Reinhold Co., New York, 1985.
 15. **Lynch PM**: The process of family registration. In: Lynch PM, Lynch HT (eds). *Colon Cancer Genetics*. Van Nonstrand Reinhold Co., New York, 1985.
 16. **Lynch PM**: Jurisprudential considerations in the evaluation and screening of high risk patients. In: P Rozen, SJ Winawer (eds). *Secondary Prevention of Colorectal Cancer: An International Perspective*. *Frontiers of Gastrointestinal Research* (10), S. Karger, Basel, 1986.
 17. Wargovich MJ, Levin B, **Lynch PM**, Sumiyoshi H, Baer A, Isbell G, Hu PJ, Roubain L, Winn R. Calcium regulation of colon epithelial cytokinetics in high risk subjects for colon cancer: application of new proliferation markers. In: Utsunomiya J, Lynch HT (eds). *Hereditary Colon Cancer*, Springer-Verlag, Tokyo; 1990, pp 265-70.
 18. Cristofaro G, Di Giulio E. DI Giulio, Mingazzini PL, Bufo P, Senatore S, **Lynch PM**, Watson P, Lynch JF, Lynch HT. Medical/legal concerns in the management of patients from Lynch syndromes kindreds. In: J Utsunomiya, HT Lynch (eds). *Hereditary Colon Cancer*, Springer-Verlag, Tokyo; 1990, pp 193-01.
 19. **Lynch PM**, Winn RJ, Wargovich MJ, Levin B. Hereditary non-polyposis colorectal cancer: The University of Texas M. D. Anderson Cancer Center experience. In: *Hereditary Colon*

- Cancer*. J Utsunomiya, HT Lynch (eds). Springer-Verlag, Tokyo; 1990, pp 185-91.
20. **Lynch PM**. Polyposis syndromes. In: Haubrich, Schaffner, Berk (eds). *Bockus Gastroenterology* 5th edition Volume 2, WB Saunders, Philadelphia; 1990, pp1731-43.
 21. **Lynch PM**. Familial cancer management: legal aspects. In: *Familial Cancer Management* Weber W, Mulvihill JJ, Narod SA (eds). CRC Press, Inc., Boca Raton. 1996. pp159-174.
 22. **Lynch PM**. Biology of colorectal cancer: An overview of genetic factors. In: *Management of Colorectal Cancer*. Bleiberg H, Rougier P, and Wilke H-J (eds). Martin Dunitz Ltd., London. 1998. pp 1-17.
 23. **Lynch PM**. Colorectal cancer: screening and primary prevention. In: *Gastrointestinal Cancer*. Ajani JA, Curley SA, Janjan NA, **Lynch PM** (eds.) Springer Science+Business Media, Inc., New York. 2005. pp 85-103.
 24. **Lynch PM**. The role of inheritance in the diagnosis and management of gastrointestinal malignancies. In: *The Principles and Practice of Gastrointestinal Oncology*. Abbruzzese, Evans, Willett, and Hamilton (eds). Oxford University Press, New York. (In press)
 25. Swisher SG, Komaki R, **Lynch PM**, Ajani JA. Esophageal carcinoma. (Submitted)
 26. **Lynch PM**. How can I help with research? In: *Colorectal Cancer Can Run in the Family*. Macrae F (ed). Medcom Asia Pacific, Victoria, Australia. (Submitted)
 27. Wallace M, **Lynch PM**. Primary prevention of colorectal cancer (diet and chemoprevention). In: *Frontiers in Surgery*. (Submitted)
 28. Wallace M, **Lynch PM**. The current status of chemoprevention in FAP. In: *Familial Cancer on FAP* (Submitted)

g. Books

1. Ajani JA, Curley SA, Janjan NA, **Lynch PM** (eds.). *Gastrointestinal Cancer*. Springer Science+Business Media, Inc., New York. 2005.

h. Letters to the Editor

1. Lynch HT, Harris RE, Guirgis HA, **Lynch PM**, Maloney K, Rankin L, Lynch J. Early age of onset and familial breast cancer. *Lancet* September 18, 1976.
2. Lynch HT, **Lynch PM**, Harris RE. Proximal colon cancer in familial carcinoma of the colon exclusive of familial polyposis coli. *Lancet* i:1306-1307.
3. **Lynch PM**. Commentary on: Jagelman D: Extra-colonic manifestations of familial adenomatous polyposis. *Oncology* (5)2:23-27, 1991.
4. **Lynch PM**, Wargovich MJ. Re: Proliferation rate in hereditary non-polyposis colon cancer. *J Natl Cancer Inst* 83:1688-89, 1991.

i. Manuals, Teaching Aids, Other Publications

1. Weber BL, Olopade OI, Blackwood MA, Cummings S, Eng C, Garber JE, Lynch PM, Offit K, Rodriguez-Bigas MA, Tomlinson G, Tranin AS (eds). *ONCOSEP: Genetics, Oncology Self-Education Program*. Kendall/Hunt Publishing Company, Dubuque. 2000.

j. Other – N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Boards

Medical Editor, MDACC Newsletter on Hereditary Colon Cancer “Generation to Generation,” 1991-

Editorial Committee, *Disease Markers*, 2000-

Member, NCI PDQ Cancer Genetic Editorial Board, 2002 –

Section Editor, Epidemiology, Pharmacogenomics, and Hereditary Cancer of the Colon and Rectum, *Current Colorectal Cancer Reports*, November 2005

Member, Editorial Board, *Journal of Clinical Oncology* , 2006 – 2008

Journal Reviewer

Reviewed manuscripts for *Gastroenterology*, *Cancer*, *Digestive Diseases & Sciences*, *American Journal of Gastroenterology*, *International Journal of Cancer*, *International Journal of Radiation Oncology*, *Journal of Clinical Oncology*, 1992-

TEACHING

Within Current Institution

Formal Teaching

Courses Taught - N/A

Training Programs

Faculty, Flexible Sigmoidoscopy: Learning Module for Family Practice Residents, 1988-1992

Other Educational Programs

Coordinator, GI Pathology Conference, 1990-

Coordinator, GI Research Forum, UT M.D. Anderson Cancer Center/UT Health Science Center Houston/Baylor, 1994-1995

Faculty, “Gastrointestinal Cancer Precursors,” Medical Oncology Board Review Course, 9/13/1995

Faculty, "Colorectal Cancer: Screening and Surveillance," Medical Oncology Board Review Course, 2/4/2000

Faculty, "Screening and Surveillance for Colorectal Cancer," Medical Oncology Board Review Course, 10/11/2001; 10/7/2002

Lecturer, "Colorectal Cancer," Fundamentals of Clinical Medicine, UT Medical School at Houston, 2/27/2003

Faculty Moderator, Esophagoscopy and Endoscopic Esophageal Ultrasonography; Barretts Esophagus, Baylor Cardiothoracic Surgery Lecture Series, Houston, Texas, 3/19/2003

Faculty, "Colon Cancer," Day of Science – "Meet the Experts" Session, 5/22/2003

Faculty, "Colonoscopy Overview," Med-Ed Program, 7/24/2003

Faculty, "Screening and Surveillance for Colorectal Cancer," 2003 Comprehensive Board Review in Hematology and Medical Oncology, 10/11/2003

Faculty, "Screening and Surveillance for Colorectal Cancer," 2004 Comprehensive Board Review in Hematology and Medical Oncology, 9/28/2004

Supervisory Teaching

Advisory Committees - N/A

Supervisory Committees - N/A

Direct Supervision

Undergraduate and Allied Health Students - N/A

Medical Students

Lectures to freshman medical class (Legal Medicine), Creighton University: a) Physician-Patient Relationship; b) Physician Licensure; c) Informed Consent; d) Medical Malpractice; e) Health Maintenance Organizations (HMOs), 1976-1981

Graduate Students

Faculty, "Genetic Counseling in Colorectal Cancer," UT Houston Genetic Counseling Course, 7/21/1995

Faculty, UT Houston Genetic Counseling (Masters Program), Lectures on Inherited GI Cancer Susceptibility/Student Clinic Preceptors, 1997-present

Residents and Fellows

Faculty, GI endoscopy and clinical teaching, GI Fellowship Program, UT Health Science Center Houston/M.D. Anderson Cancer Center, 1988-

Outside of Current Institution

Organization of National or International Conferences/Symposia

Leeds Castle Polyposis Group Biennial Meeting, Venice, Italy, Session Chairman, 4/28/2001

Collaborative Group of Americas on Inherited Colorectal Cancer Annual Meeting, San Diego, CA, member, Planning Committee, 10/12-13/2001

Collaborative Group of Americas on Inherited Colorectal Cancer Annual Meeting, Baltimore, MD, member, Planning Committee, 10/13-14/2002

Collaborative Group of Americas on Inherited Colorectal Cancer Annual Meeting, Toronto, Canada, Chair Working Group Session: DFMO Study, 10/22-24, 2004

International Society for Gastrointestinal Hereditary Tumours (InSiGHT), Newcastle, UK, Co-Chair Free Paper Session, 6/17/2005

Collaborative Group of Americas on Inherited Colorectal Cancer Annual Meeting, Salt Lake City, Utah, member, Planning Committee, 10/23-24/2005

Presentations at National or International Conferences

Invited

Invited speaker, "State of the Art Lecture: Genetics & GI Cancer," "Chemoprevention in GI Neoplasia," "Screening/Surveillance in Colorectal Cancer," Brasil Gastro-enterological Association Annual Meeting, Porto Alegre, Brasil, 11/21/1994

Invited speaker, "Prevention of Colorectal and Gastric Carcinoma: Colon Carcinoma-Clinical Trials," "Molecular Biology of Tumor Development of Colorectal Cancer," Second Int'l Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Cologne, Germany, 1/11/1995

Invited speaker, "Legal Considerations in Genetic Counseling for Inherited Colorectal Cancer," Genetic Screening for Colorectal Cancer-NIH Workshop, Bethesda, MD, 4/10/1995

Invited speaker, "Hereditary Nonpolyposis Colorectal Cancer: Issues in Diagnosis and Management," Applying Molecular Genetics to Cancer Detection and Management: An Update for Practicing Clinicians, Washington, DC, 9/9/1995

Invited speaker, "Predisposition Testing: Hereditary Cancer," International Workshop: Progress in Laboratory Testing of Solid Tumors, Klais, Upper Bavaria, Germany, 10/12/1995

Invited speaker, “Endoscopic Ultrasound; Lasers in GI Disease,” Third Course of Actualization in Gastroenterology: Diagnostic Methods and Treatment, San Luis Potosi, Mexico, 11/1/1996

Invited speaker, “Contemporary Issues in the Management of FAP/HNPCC,” ACS National Conference on State of the Art in Cancer Genetics: Societal and Clinical Implications of DNA Testing, Dallas, TX, 2/21/1997

Invited speaker, “Psychosocial, Legal, and Ethical Issues in Predisposition Testing and Counseling in HNPCC,” UICC Symposium on Familial Cancer and Prevention and Molecular Epidemiology, Kobe, Japan, 5/14/1997

Invited speaker, “HNPCC: Predisposition Testing and Its Application to Clinical Practice,” Symposium on HNPCC, Naples, Italy, 6/10/1997

Invited speaker, “Hereditary Colon Cancer: Syndrome and Management,” ASCO Train the Trainer Workshop, Chicago, IL, 6/21/1997

Invited speaker, “Molecular Carcinogenesis in Colon Cancer,” UICC Cancer Management Meeting, Vienna, Austria, 7/1/1997

Invited speaker, “Genetic Testing for Hereditary Colon Cancer,” Third Annual Strategies for Cure: GI Malignancies Providence Cancer Center, Dearborn, MI, 9/12/1997

Invited speaker, “Genetic Testing in FAP/HNPCC: Implication for Counseling and Management,” Fall Meeting of the Carolinas Genetics Conclave, University of South Carolina, Columbia, SC, 9/26/1997

Invited speaker, “Genetic Counseling – A Scientific, Medical, and Legal Challenge,” Annual Joint Meeting of German and Austrian Societies for Hematology & Oncology, Linz, Austria, 10/14/1997

Invited speaker, “Genetic Testing/Guidelines/Ethics – When to Test & What to Do with the Results,” ASCO Fall Education Conference, Orlando, FL, 11/9/1997

Invited speaker, “The Hereditary Cancer Syndromes: Surveillance and Therapeutic Options,” Conference Counseling People about Hereditary Cancer, 11/14/1997

Invited speaker, “Biology and Prevention of GI Malignancies; Biology of Colorectal Cancer and Hereditary Aspects,” International Update on Gastro-Intestinal Malignancies, New Delhi, India, 12/20/1997

Invited speaker, “Hereditary Colorectal Cancer: Genetic Testing, Chemoprevention, and Clinical Management,” Association of Northern California Oncologists, San Francisco, CA, 3/14/1998

Invited speaker, “Hereditary Colorectal Cancer: Genetic Testing, Chemoprevention, and Clinical Management,” 115th Annual Meeting of the German Society of Surgery, Berlin,

Germany, 4/29/1998

Invited speaker, “Genetic Testing for Gastrointestinal Cancers: APC, HNPCC,” ASCO Cancer Genetics Satellite Symposium: The Emerging Role of Genetics in Clinical Cancer Care, Los Angeles, CA, 5/15/1998

Invited speaker, “Clinical Challenges of Management of FAP and HNPCC,” American Cancer Society 2nd National Conference on Cancer Genetics, San Francisco, CA, 6/27/1998

Invited speaker, “Predisposition Testing and Management of Inherited Colorectal Cancer,” Cancer Genetics Symposium, New York, NY, 9/24/1998

Invited speaker, “Introduction to Colorectal Cancer – Epidemiology, Diagnosis and Staging,” “The Use of Lasers and Stenting in the Management of Colorectal Cancer,” “Introduction to Esophageal Cancer – Epidemiology, Diagnosis and Staging,” “The Use of Lasers, Stenting, and Photodynamic Therapy (PDT) in the Management of Esophageal Cancer,” Peruvian Medical Oncology Society Conference: A Multidisciplinary Approach to Gastrointestinal Cancers, Peru, 10/3/1998

Invited speaker, “Susceptibility Testing in Hereditary Colon Cancer: Impact on Management,” American College of Surgeons, Orlando, FL, 10/27/1998

Invited speaker, “Molecular Biology and Clinical Aspects of FAP,” M.D. Anderson Cancer Center Conference: Biologic Principles for the Therapy of Human Colon Cancer, San Diego, CA, 11/5/1998

Invited speaker, “Evaluation and Management of Hereditary Colorectal Cancers,” ASCO Cancer Genetics Satellite Symposium, Chicago, IL, 11/13/1998

Invited speaker, “HNPCC, Genetic Testing, and Current and Future Research,” 10th International Scientific Congress of the Egyptian Medical Syndicate: Basic & New Modalities in Diagnosis and Management, Cairo, Egypt, 12/12/1998

Invited speaker, “Inherited Colorectal Cancer: FAP and HNPCC,” ASCO Train the Trainer Update Workshop, New Orleans, LA, 3/21/1999

Invited speaker, “Society, Ethics & Hereditary Cancer,” 2nd Joint Meeting of the Leeds Castle Polyposis & International Collaborative Group for Hereditary Non Polyposis Colorectal Cancer, Lorne, Australia, 3/5/1999

Invited speaker, “Flexible Sigmoidoscopy,” UT M.D. Anderson Cancer Center Primary Care Oncology Screening and Prevention Conference, Orlando, FL, 4/8/1999

Invited speaker, “Identification of High Risk Groups, Molecular Diagnostics and Management of Hereditary Colon Cancers,” “Diagnostic Endoscopy Techniques and Ultrasound,” “The Use of Lasers and Stenting for Unresectable Esophageal Cancer,” M.D. Anderson Cancer Center Symposium at Albert Einstein Hospital, Sao Paulo, Brazil, 4/8/1999

Invited speaker, "Management of Hereditary Colon Cancer: FAP and HNPCC," New Mexico Society of Clinical Oncology, Albuquerque, NM, 4/17/1999

Invited speaker, "Evaluation and Management of Hereditary Colorectal Cancer," ASCO Cancer Genetics Satellite Symposium, Atlanta, GA, 5/14/1999

Invited speaker, "Predictive Testing & Management of Familial Colon Cancer (FAP and HNPCC)," New York State Genetics Task Force Meeting, New York, NY, 6/16/1999

Invited speaker, "Hereditary Colon Cancer: What Do Clinicians Need to Know," Instituto Portuguese do Oncologia, Lisbon, Portugal, 3/27/2000

Invited speaker, "Screening for and Advances in Endoscopic Evaluation of Colorectal Lesions," DDW Sunrise Breakfast Symposium, San Diego, California, 5/24/2000

Invited speaker, "Cyclooxygenase-2 Inhibitors and Their Use in Cancer," M.D. Anderson Cancer Center Investigators' Workshop, St. Croix, Virgin Islands, 7/14/2000

Invited speaker, "The Genetic Basis of Familial and Sporadic Colorectal Cancer," Perspectives in Colorectal Cancer Conference, San Francisco, California, 9/8/2000

Panel member, "How Does the Possible Diagnosis of HNPCC Influence Patient Management, Including Prophylactic Procedures?" "Is There a Place for Chemoprevention in HNPCC," ICG-HNPCC Meeting, Tel Aviv, Israel, 9/20/2000

Panel member, "Difficult Case Management Issues," Collaborative Group of the Americas on Inherited Colorectal Cancer, Philadelphia, Pennsylvania, 10/3/2000

Invited speaker, "Family Cancer Syndromes," International Symposium on Predictive and Preventive Oncology, Geneva, Switzerland, 10/28/2000

Invited speaker, "Genetic Tests as Standard of Care: FAP," ASCO Cancer Genetics Symposium, Orlando, Florida, 11/3/2000

Invited speaker, "Genetics in the Office: Considerations for Every New Patient," ASCO Clinical Practice Forum, Orlando, Florida, 11/4/2000

Invited speaker, "Gastroenterologists' Perspective on the Management of Family Adenomatous Polyposis and Colon Cancer: The Role of COX-2 Inhibition," Association of Gastro-Enterologists of Quebec, Montreal, Canada, 11/9/2000

Invited speaker, "Chemoprevention and Hereditary Colorectal Cancer," Istituto Nazionale Tumori, Naples, Italy, 11/15/2000

Invited speaker, "CRC: Etiology, Diagnosis and Chemoprevention in the New Milenium," "Endoscopic Treatment of CRC: A Cure through the Scope," Puerto Rico Gastrointestinal Association Digestive Disease at the Caribbean Conference, San Juan, Puerto Rico,

3/10/2001

Invited speaker, "COX-2 Inhibitors in FAP and Potential Applications for Established Tumors," Society of Surgical Oncology Annual Cancer Symposium, Washington, D.C., 3/15/2001

Invited speaker, "Prophylactic Surgery for HNPCC Patients," Symposium on Advances in Surgical Oncology, Biel, Switzerland, 5/25/2001

Invited speaker, "Endoscopy and Treatment in Colorectal Cancer," M.D. Anderson Cancer Center Multidisciplinary Management of GI Malignancies Conference, Maui, Hawaii, 2/13/2002

Invited speaker, "New Horizons in Desmoid Tumor Treatment," Hereditary Colon Cancer Association (HCCA) Annual Conference, San Antonio, Texas, 3/15/2002

Invited speaker, "Cancer Genetics at the Bedside: Managing Aspects of Hereditary Cancers," ASCO Annual Meeting, Orlando, Florida, 5/18/2002; 5/20/2002

Invited speaker, "Prophylactic Colectomy in Colorectal Cancer," American Association for Cancer Research (AACR), Boston, Massachusetts, 10/15/2002

Invited speaker, "Biology of Hereditary Colorectal Cancer;" "Advances in Therapeutic Endoscopy," 14th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, 2/2/2003

Invited speaker, "Rare Syndromes and Genetic Testing;" "Genetic Testing and Counseling;" "Risk-based Screening and Surveillance," 4th Annual Conference on Gastrointestinal Cancer, University of Utah, Park City, Utah, 3/20/2003

Invited speaker, "High Risk Populations," 35th Annual Southeastern Wisconsin Cancer conference, Milwaukee, Wisconsin, 3/22/2003

Invited speaker, "Genetic Testing for HNPCC and FAP: In Whom, When and for What?" American Society of Colon and Rectal Surgeons Symposium, New Orleans, Louisiana, 6/22/2003

Panel member, "Chemoprevention: If the Capp Fits..." Combined meeting of the ICG/LCPG, Cleveland, Ohio, 9/5/2003

Invited speaker, "Hereditary Colorectal Cancer Syndromes" ASCO Genetics Categorical Course Session, New Orleans, Louisiana, 6/7/2004

Invited speaker, "Genetics of Colorectal Cancer: Who Should be Screened?" 11th International Conference on Gastrointestinal Cancer: Colorectal Cancer, Arcachon, France, 10/16/2004

Invited speaker, "Chemoprevention in FAP: State of the Art" Italian Association for

Familial and Hereditary Cancer of the Gastrointestinal Tract, Naples, Italy, 11/11/2004

Invited speaker, "Role of the Gastroenterologist in Screening and Treatment of Colonic Polyps" 2nd Multidisciplinary Management of Gastrointestinal Malignancies, Kauai, Hawaii, 11/17/2004

Invited speaker, "Future Directions in Anti Adenoma Therapy in FAP" St. Mark's 2004 Frontiers in Intestinal and Colorectal Disease Conference, London, UK, 12/2/2004

Invited speaker, "The Lawyer's Point of View" The Medico-Legal Implications of Caring for Patients and Families with hereditary Colorectal Cancer Syndromes Symposium, American Society of Colon & Rectal Surgeons, Philadelphia, PA, 5/4/2005

Invited Speaker, "Colonoscopy in a Phase I Safety Trial of Celecoxib in Children with FAP" International Society for Gastrointestinal Hereditary Tumours (InSiGHT), Newcastle, UK, 6/17/2005

Invited speaker, "Diagnostic and Therapeutic Advances in Endoscopy for Colorectal Neoplasia Emphasizing High-Risk Groups" 14th Chinese Endoscopists' Academic Conference, Beijing, China, 6/25/2005

Other, Including Scientific Exhibitions

Poster presentation, "Common hMSH2 mutation in unrelated families with a variable family history of colorectal cancer," Digestive Disease Week, San Diego, CA, 5/14/1995

Poster presentation, "Clinical implementation of microsatellite instability testing at a comprehensive cancer center," World Congress of Gastroenterology, Bangkok, Thailand, 2/27/2002

Debate participant, "Should population screening be introduced?" COSA/ASCO Satellite Interactive Videoconference, Sydney, Australia and Houston, Texas, 11/30/2002

Poster presentation, "The experience of cancer in HNPCC families: Findings from a qualitative study," Peterson SK, Watts BG, Vernon SW, Baile WF, **Lynch PM**, Gritz ER. Society of Behavioral Medicine 24th Annual Meeting, Salt Lake City, UT, 3/20/2003

Poster presentation, "A CPT-11-Taxotere-5-FU regimen for induction and concurrent chemoradiotherapy prior to surgery in patients with respectable esophageal or GEJ carcinoma," Swisher S, Ajani J, Komaki R, Putnam JB, Rice D, Smythe R, Vaporciyan A, Walsh G, Liao Z, Yao J, Ho L, Hamilton S, Luthra R, Rashid A, Wu TT, **Lynch P**, Faust J, Carr K, Roth J. ASCO Annual Meeting, Chicago, IL, 5/31-6/3/2003.

Seminar Invitations from Other Institutions

"Detection & Management of Inherited Colorectal Cancer," Cancer Genetic Testing and Primary Care, Roswell Park Cancer Center, Buffalo, NY, 12/3/1994

"Colon Cancer Screening," Cancer Detection Symposium, Ochsner Clinic, New Orleans, LA, 6/10/1995

- “Gastrointestinal Endoscopic Ultrasound,” St Steven Hospital, El Paso, TX, 8/9/1995
- “Screening for Colorectal Cancer,” Hoag Cancer Center Symposium: Update on Colorectal Cancer, Newport Beach, CA, 4/3/1997
- “Therapy of Common Inherited Cancers: Chemoprevention,” Columbia Gulf Coast Medical Center, Wharton, TX, 9/5/1997
- “Genetic Testing and Management of Familial Colorectal Cancer,” Sharp Memorial Hospital, San Diego, CA, 4/20/1998
- “Genetic Testing and Management of Familial Colorectal Cancer,” Centinela Hospital, Inglewood, CA, 4/21/1998
- “Colon Cancer Screening,” Loma Linda University Medical Center, Surgery Grand Rounds, Loma Linda, CA, 4/22/1998
- “Colon Cancer Screening,” St. John’s Hospital and Health Center Cancer Conference, Santa Monica, CA, 4/22/1998
- “Genetic Testing and Management of Familial Colorectal Cancer,” Western Medical Center Tumor Board, Santa Ana, CA, 4/22/1998
- “Colon Cancer Screening,” Santa Monica/UCLA Medical Center Cancer Conference, Santa Monica, CA, 4/23/1998
- “Colon Cancer Screening,” West Anaheim Medical Center, Orange, CA, 4/24/1998
- “Prevention of Colorectal Cancer,” Western Medical Center: Perspectives in Oncology Advances in Colorectal Cancer, Santa Ana, CA, 6/25/1998
- “Management of Hereditary Colon Cancer,” University of Tennessee Cancer Center & Graduate School of Medicine: Practical Issues in Cancer Genetics 1998 Conference, Knoxville, TN, 10/17/1998
- “Hereditary Nonpolyposis Colorectal Cancer: Clinical Features, Genetics, and Management,” City of Hope Comprehensive Cancer Center: Gastrointestinal Cancer Genetics and Clinical Practice Course, Duarte, CA, 1/23/1999
- “Colorectal Screening and Diagnosis,” Northeast Medical Center Hospital, Humble, TX, 2/10/1999
- “Clinical Genetics,” 1st Annual Emil Jobb Gastroenterology Symposium: Colorectal Cancer, Swedish Medical Center, Seattle, WA, 3/11/1999
- “Familial Colorectal Cancer,” Cancer Genetics Symposium, Mt. Carmel Regional Cancer Center, Pittsburg, KS, 4/24/1999
- “Dietary Risk Factors in Colon Cancer and Chemoprevention,” Gulf Coast Medical Center,

Wharton, TX, 2/4/2000

“Familial Colorectal Cancer” Molecular Diagnosis and Management,” Baptist Memorial Hospital Conference, Memphis, Tennessee, 6/3/2000

“COX II Inhibition in FAP,” St. Joseph’s Hospital, Omaha, Nebraska, 6/14/2000

“COX II Inhibition in FAP,” University of Nebraska Medical Center, Omaha, NE, 6/15/2000

“Molecular Diagnostics and Clinical Management of Familial Colon Cancer,”

“Chemoprevention Strategies in Familial Colon Cancer,” Norton Healthcare Cancer Center, Louisville, Kentucky, 9/15/2000

“Genetics of Cancer” – Keynote Address, “Genetics of Colon Cancer,” Saint Alphonsus Regional Medical Center, Boise, Idaho, 3/23/2001

“Corralling Colorectal Cancer! What is the Best Screening Tool?” Good Samaritan Hospital, Los Angeles, California, 6/30/2001

“Developments in Cancer Genetics: Colorectal Cancer as a Model,” Aultman Institute Cancer Conference, Canton, Ohio, 9/6/2001

“Advances in Cancer Prevention for Families at Risk for Cancer,” The Anderson Network Circle of Life Conference, Houston, TX, 9/8/2001

“Identifying Hereditary Dispositions and Screening High Risk Groups for Colon Cancer,” Del Sol Medical Center, El Paso, Texas, 11/29/2001

“Colon Cancer,” Hendrick Medical Center Fall Symposium, Abilene, Texas, 9/6/2002

“‘Accepted’ Screening Modalities,” Presbyterian Hospital of Dallas, Dallas, Texas, 9/21/2002

“Familial Colon Cancer Predisposition: Genetics, Counseling & Testing;” “Colon Cancer Chemoprevention: What Your Patient Needs to Know,” Eastern Maine Medical Center, Bangor, Maine, 9/26/2002

“Hereditary Colon Cancer Syndromes: Genetics and Clinical Manifestations,” Presbyterian Hospital of Dallas, Dallas, Texas, 10/23/2002

“Colorectal Cancer,” Gastrointestinal Cancers Conference, Saint Louis University School of Medicine, St. Louis, Missouri, 10/26/2002

“Barrett’s Esophagus,” Christus St. Frances Cabrini Hospital, Alexandria, Louisiana, 2/11/2003

“Management including Chemoprevention in High Risk Groups for Colorectal Cancer,” Grand Rounds, UT Health Science Center, Department of Surgery, San Antonio, Texas, 3/31/2003

Lectureships and Visiting Professorships - N/A

Other Presentations (state, local) Conferences

“Clinical Updates on Colorectal and Skin Cancer,” Breast & Cervical Cancer Control Program (BCCP) Conference, San Antonio, TX, 3/5/1998

“Surveillance and Therapeutic Options of Cancer Risk Screening,” Texas Genetics Network Annual Conference, San Antonio, TX, 8/28/1998

“Flexible Sigmoidoscopy,” Texas Academy of Family Physicians 10th Annual primary Care for the 90’s Conference, Houston, TX, 10/24/1998

Workshop “Flexible Sigmoidoscopy,” Texas Academy of Family Physicians Annual Scientific Assembly, Austin, Texas, 7/28/2000

“Colorectal Cancer Rediscovered: How to Keep Your Patients Out of Trouble,” Texas Academy of Family Physicians Primary Care 2000, Houston, Texas, 10/20/2000

“Screening of Moderate and High Risk Populations Future Screening Techniques,” Texas Medical Association Physician Oncology Education Program, Fort Worth, Texas, 2/2/2002

“Colon Cancer Awareness,” Central Market Speakers Project, Houston, Texas, 3/13/2002

“Genetics and Management of Familial Adenomatous Polyposis: the Program at MDACC,” Division of Internal Medicine CME Conference, M.D. Anderson Cancer Center, Houston, Texas, 4/22/2002

“Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous Polyposis,” Myriad Genetics Educational Program, Austin, Texas, 8/13/2002

“High Risk Populations,” Texas Medical Association Physician Oncology Education Program/American Cancer Society, Houston, Texas, 3/15/2003

“Genetic Testing of Gastrointestinal Disorders,” The 28th Annual Texas Program, The Texas Society for Gastroenterology and Endoscopy/American College of Gastroenterology, Galveston, Texas, 9/14/2003

“Hereditary Cancers in your Practice: What Oncologists Need to Know,” Myriad Genetics Educational Program, Houston, Texas 11/18/2003

“Hereditary Colon Cancer,” Internal Medicine Grand Rounds, Wilford Hall Medical Center, San Antonio, Texas, 1/21/2004

“Hereditary Colon Cancer,” UT Health Science Center GI Conference, San Antonio, Texas, 1/22/2004

“Colon Cancer Prevention Update,” 15th Annual Community Oncology Program (CCOP), Houston, Texas, 2/13/2004

“Colorectal Cancer Prevention and Screening with Emphasis on High Risk Groups,” Polly Ryon Hospital, Richmond, Texas, 5/20/2004

“Screening and Prevention of Colon Cancer,” TMA Cancer Prevention Conference, Lubbock, Texas, 4/9/2005

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities

Local/State

Houston Gastroenterological Association, Member

Texas Society of Gastrointestinal Endoscopy, Member

National and International

Advisory Committee: Cooperative Family Registry for Colorectal Cancer Studies, Member, 1997-

Alpha Omega Alpha Honorary Medical Society, Member

American Gastroenterological Association, Member

Chairman, Subcommittee on Colorectal Cancer, Clinical Teaching Program (CTP) Committee of the AGA, 1992-1998

American Society of Clinical Oncology

Member, Subcommittee on Cancer Genetic Testing, 1995-2000

Member, Task Force on Cancer Genetics Education, 1997-2000

American Society for Gastrointestinal Endoscopy, Member

American Society of Law, Medicine & Ethics, Member

Cancer Studies Consortium Task Force on Preventive Recommendations, Member, 1995-2000

International Collaborative Group on Hereditary Non-polyposis Colorectal Cancer, Member

Leeds Castle Polyposis Group, Member

Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA), Member

President, 2000-2001

Council member, 2001 – present

International Society for Gastrointestinal Hereditary Tumours, Member

Council Member, 2003 – present